Full Year 2024 Results Key Financial Results Net loss: US$59.6m (loss narrowed ...

BofA analyst Alec Stranahan lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $1 from $4 and keeps an Underperform rating on ...

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 18.12% and 144%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Reports Q4 revenue $366k, consensus $718.26k. “We believe that our SERENITY program presents an exciting opportunity to address a substantial ...

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 ...

The Chattogram City Corporation (CCC) has begun an experimental deployment of Bacillus thuringiensis israelensis (BTI), a ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ...

Rodman & Renshaw began coverage on shares of BioXcel Therapeutics (NASDAQ:BTAI – Free Report) in a report issued on Wednesday morning,Benzinga reports. The firm issued a buy rating and a $65.00 target ...

Fintel reports that on March 19, 2025, Rodman & Renshaw initiated coverage of BioXcel Therapeutics (NasdaqCM:BTAI) with a Buy ...

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, ...

The latest price target for BioXcel Therapeutics (NASDAQ:BTAI) was reported by Rodman & Renshaw on March 19, 2025. The analyst firm set a price target for $65.00 expecting BTAI to rise to within ...